REG - Roquefort Theraptcs. - Results of AGM

Roquefort TherapeuticsAnnouncement

29/06/2023 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230629:nRSc3755Ea&default-theme=true

RNS Number : 3755E  Roquefort Therapeutics PLC  29 June 2023

29 June 2023

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Results of AGM

 

Roquefort Therapeutics (LSE:ROQ, OTCQB: ROQAF), the Main Market listed biotech
company focused on developing first in class medicines in the high value and
high growth oncology market, is pleased to announce that at the Company's
Annual General Meeting ("AGM") held earlier today, all resolutions proposed
were duly passed.

 

The resolutions were put to shareholders via a poll, the results of which were
as follows:

 Resolution      Poll Results                              Total Votes Withheld*
         For     Against     Total Votes Cast
 1       Shares  21,890,925  -                 21,890,925  -
         %       100.00%     -
 2       Shares  21,890,885  20                21,890,905  20
         %       100.00%     0.00%
 3       Shares  21,890,885  20                21,890,905  20
         %       100.00%     0.00%
 4       Shares  10,257,712  2,713             10,260,425  11,630,500
         %       99.97%      0.03%
 5       Shares  21,890,925  -                 21,890,925  -
         %       100.00%     -
 6       Shares  21,890,885  20                21,890,905  20
         %       100.00%     0.00%
 7       Shares  21,890,925  -                 21,890,925  -
         %       100.00%     -
 8       Shares  21,890,905  20                21,890,925  -
         %       100.00%     0.00%
 9       Shares  21,885,885  20                21,885,905  5,020
         %       100.00%     0.00%
 10      Shares  21,855,276  35,629            21,890,905  20
         %       99.84%      0.16%
 11      Shares  21,885,071  573               21,885,644  5,281
         %       100.00%     0.00%

* Votes withheld are not counted in the calculation of the proportion of votes
for and against a resolution.

 

The total number of ordinary shares in issue on 27 June 2023, the deadline for
casting votes by proxy in advance of the AGM, was 129,149,998 shares.  17% of
voting capital was instructed in respect of the resolutions put to the AGM.

 
Enquiries:

 

 Roquefort Therapeutics plc
 Stephen West (Chairman) / Ajan Reginald (CEO)  +44 (0)20 3918 8633

 Hybridan LLP (Joint Broker)

 Claire Louise Noyce                            +44 (0)203 764 2341

 Optiva Securities Limited (Joint Broker)
 Christian Dennis                               +44 (0)20 3411 1881

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale       +44 (0)20 7466 5000

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech
company developing first in class drugs in the high value and high growth
oncology segment prior to partnering or selling to big pharma.

 

Since listing in March 2021, Roquefort Therapeutics has successfully acquired
Lyramid Pty Limited, a leader in the development of medicines for a new
therapeutic target, Midkine (a human growth factor associated with cancer
progression), and most recently acquired Oncogeni Ltd, founded by Nobel
Laureate Professor Sir Martin Evans, which has developed two families of
innovative cell and RNA oncology medicines.

 

Roquefort Therapeutics' portfolio consists of five fully funded, novel
patent-protected pre-clinical anti-cancer medicines.  The highly
complementary profile of five best-in-class medicines consists of:

·    Midkine antibodies with significant in vivo efficacy and toxicology
studies;

·    Midkine RNA therapeutics with novel anti-cancer gene editing action;

·    Midkine mRNA therapeutics with novel anti-cancer approach;

·    STAT-6 siRNA therapeutics targeting solid tumours with
significant in vivo efficacy; and

·    MK cell therapy with direct and NK-mediated anti-cancer action

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)
 and @RoquefortTherap on Twitter.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFIFLTRVIAFIV